Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukemia
Normalized, scaled metabolite abundance data from an experiment involving profiling of diagnostic bone marrow plasma samples from N=155 children with acute lymphoblastic leukemia. Patients were diagnosed at Texas Children's Hospital between 2007-15 and treated on or according to Children's Oncology Group frontline ALL protocols. Metabolomics data were generated from 2017-18 using the Metabolon Global Metabolomics platform. Missing values have been imputed with the minimum. Data are annotated with sex; race/ethnicity; height, weight, age, and white blood cell count at diagnosis; NCI risk group; cytogenetic category; central carbon metabolism cluster membership derived from metabolite set enrichment analysis and hierarchical clustering analyses; end-induction minimal residual disease (MRD) status; and relapse status if known. Data are divided into a discovery (N=93) and replication (N=62) partition.